Clene to Present at Upcoming September Investor Conferences
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) announced its participation in two upcoming investor conferences in September 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) announced its participation in two upcoming investor conferences in September 2022. The first is Citi’s 17th Annual BioPharma Conference on September 8, 2022, in Boston, followed by H.C. Wainwright's 24th Annual Global Investment Conference on September 12-13, 2022, in New York. Clene's lead asset, CNM-Au8, is a treatment for multiple sclerosis and amyotrophic lateral sclerosis that enhances neuronal health through gold nanocrystals. More information can be found on their website.
Details
News Market Reaction – CLNN
The recorded move for CLNN in the trading session of this news was -0.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will participate in the following investor conferences in September:
Citi’s 17th Annual BioPharma Conference
Date: September 8, 2022
Location: Four Seasons Hotel, Boston, MA
Format: 1x1 meetings
H.C. Wainwright 24th Annual Global Investment Conference
Dates: September 12-13, 2022
Location: Lotte New York Palace Hotel, New York, NY
Date, Time and Location of Presentation: September 13, 2022, at 12:00 ET (Kennedy I)
Format: Corporate Presentation and 1x1 meetings
About CNM-Au8®
CNM-Au8 is Clene’s lead asset in mid- and late-stage clinical development for the treatment of multiple sclerosis and amyotrophic lateral sclerosis. An oral suspension of gold nanocrystals, CNM-Au8 was developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc.
About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.
Media Contact
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310
Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.